Challenges in the diagnosis and management of acromegaly: a focus on comorbidities

Challenges in the diagnosis and management of acromegaly: a focus on comorbidities

Author Abreu, Alin Google Scholar
Pinzon Tovar, Alejandro Google Scholar
Castellanos, Rafael Google Scholar
Valenzuela, Alex Google Scholar
Gomez Giraldo, Claudia Milena Google Scholar
Castellanos Pinedo, Alejandro Google Scholar
Pantoja Guerrero, Doly Google Scholar
Builes Barrera, Carlos Alfonso Google Scholar
Ignacio Franco, Humberto Google Scholar
Ribeiro-Oliveira, Antonio, Jr. Google Scholar
Vilar, Lucio Google Scholar
Jallad, Raquel S. Google Scholar
Duarte, Felipe Gaia Google Scholar
Gadelha, Monica Google Scholar
Boguszewski, Cesar Luiz Google Scholar
Abucham, Julio Autor UNIFESP Google Scholar
Naves, Luciana A. Google Scholar
Musolino, Nina Rosa C. Google Scholar
Justamante de Faria, Maria Estela Google Scholar
Rossato, Ciliana Google Scholar
Bronstein, Marcello D. Google Scholar
Abstract Acromegaly is a rare, insidious disease resulting from the overproduction of growth hormone (GH) and insulin-like growth factor 1 (IGF-1), and is associated with a range of comorbidities. The extent of associated complications and mortality risk is related to length of exposure to the excess GH and IGF-1, thus early diagnosis and treatment is imperative. Unfortunately, acromegaly is often diagnosed late, when patients already have a wide range of comorbidities. The presence of comorbid conditions contributes significantly to patient morbidity/mortality and impaired quality of life. We conducted a retrospective literature review for information relating to the diagnosis of acromegaly, and its associated comorbidities using PubMed. The main aim of this review is to highlight the issues of comorbidities in acromegaly, and to reinforce the importance of early diagnosis and treatment. Successful management of acromegaly goes beyond treating the disease itself, since many patients are diagnosed late in disease evolution, they present with a range of comorbid conditions, such as cardiovascular disease, diabetes, hypertension, and sleep apnea. It is important that patients are screened carefully at diagnosis (and thereafter), for common associated complications, and that biochemical control does not become the only treatment goal. Mortality and morbidities in acromegaly can be reduced successfully if patients are treated using a multimodal approach with comprehensive comorbidity management.
Keywords Acromegaly diagnosis
Acromegaly comorbidities
Latin America
xmlui.dri2xhtml.METS-1.0.item-coverage New York
Language English
Sponsor Ipsen
Date 2016
Published in Pituitary. New York, v. 19, n. 4, p. 448-457, 2016.
ISSN 1386-341X (Sherpa/Romeo, impact factor)
Publisher Springer
Extent 448-457
Origin http://dx.doi.org/10.1007/s11102-016-0725-2
Access rights Closed access
Type Article
Web of Science ID WOS:000379350000014
URI https://repositorio.unifesp.br/handle/11600/57508

Show full item record




File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account